• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

奥拉帕利治疗携带胚系突变的治疗相关神经内分泌前列腺癌

Treatment-related neuroendocrine prostate cancer with germline mutation treated with olaparib.

作者信息

Ikeda Riko, Matsuoka Yoh, Inoue Masaharu, Ishikawa Ayataka, Akagi Kiwamu, Kageyama Yukio

机构信息

Department of Urology Saitama Cancer Center Saitama Japan.

Department of Pathology Saitama Cancer Center Saitama Japan.

出版信息

IJU Case Rep. 2023 Dec 8;7(2):115-119. doi: 10.1002/iju5.12679. eCollection 2024 Mar.

DOI:10.1002/iju5.12679
PMID:38440716
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10909146/
Abstract

INTRODUCTION

The efficacy of olaparib for treatment-related neuroendocrine prostate cancer is unknown. Here, we report a case of treatment-related neuroendocrine prostate cancer with a mutation that was treated with olaparib with 1-year efficacy.

CASE PRESENTATION

A 75-year-old man initially diagnosed with prostate adenocarcinoma developed treatment-related neuroendocrine prostate cancer after 10-year androgen deprivation therapy. Despite the initial temporary effects of etoposide and carboplatin, the patient experienced prostate bed tumor recurrence 1 year after chemotherapy cessation. FoundationOne® detected a gene mutation, and olaparib was initiated after repeating one chemotherapy course using the same chemotherapeutic agents. The patient received olaparib with sustained tumor regression for 1 year without severe side effects.

CONCLUSION

Olaparib may be the treatment of choice for treatment-related neuroendocrine prostate cancer in patients with mutations.

摘要

引言

奥拉帕利治疗相关性神经内分泌前列腺癌的疗效尚不清楚。在此，我们报告一例治疗相关性神经内分泌前列腺癌患者，该患者存在一种突变，接受奥拉帕利治疗，疗效达1年。

病例介绍

一名75岁男性最初被诊断为前列腺腺癌，在接受10年雄激素剥夺治疗后发生治疗相关性神经内分泌前列腺癌。尽管依托泊苷和卡铂最初有暂时疗效，但患者在化疗停止1年后出现前列腺床肿瘤复发。FoundationOne®检测到一种基因突变，在使用相同化疗药物重复一个化疗疗程后开始使用奥拉帕利。该患者接受奥拉帕利治疗后肿瘤持续消退1年，且无严重副作用。

结论

对于存在特定突变的治疗相关性神经内分泌前列腺癌患者，奥拉帕利可能是治疗的选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6335/10909146/cfab5559f9af/IJU5-7-115-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6335/10909146/30415640f4da/IJU5-7-115-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6335/10909146/67853ec7a830/IJU5-7-115-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6335/10909146/cfab5559f9af/IJU5-7-115-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6335/10909146/30415640f4da/IJU5-7-115-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6335/10909146/67853ec7a830/IJU5-7-115-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6335/10909146/cfab5559f9af/IJU5-7-115-g003.jpg

相似文献

1
Treatment-related neuroendocrine prostate cancer with germline mutation treated with olaparib.奥拉帕利治疗携带胚系突变的治疗相关神经内分泌前列腺癌
IJU Case Rep. 2023 Dec 8;7(2):115-119. doi: 10.1002/iju5.12679. eCollection 2024 Mar.
2
Two cases of CRPC with mutation treated by olaparib after favorable response to cisplatin.两例对顺铂治疗有良好反应后接受奥拉帕利治疗的携带突变的去势抵抗性前列腺癌（CRPC）病例。
IJU Case Rep. 2022 Oct 9;6(1):37-40. doi: 10.1002/iju5.12543. eCollection 2023 Jan.
3
Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.胚系BRCA2突变的转移性去势抵抗性前列腺癌对奥拉帕利的反应：一例报告
BMC Med Genet. 2018 Oct 17;19(1):185. doi: 10.1186/s12881-018-0703-9.
4
Frameshift Mutation in de novo Small-Cell Neuroendocrine Carcinoma of the Prostate: A Case Report.前列腺原发性小细胞神经内分泌癌中的移码突变：一例报告
Case Rep Oncol. 2023 Aug 14;16(1):621-627. doi: 10.1159/000531134. eCollection 2023 Jan-Dec.
5
A case of double-negative prostate cancer with mutation and high tumor mutation burden treated sequentially with olaparib and pembrolizumab.一例具有突变且肿瘤突变负荷高的三阴性前列腺癌患者先后接受奥拉帕利和帕博利珠单抗治疗。
IJU Case Rep. 2024 Aug 4;7(5):395-398. doi: 10.1002/iju5.12766. eCollection 2024 Sep.
6
Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.BRCA2 突变型治疗相关神经内分泌前列腺癌患者的脑转移及放疗和奥拉帕利长期疗效：病例报告及文献复习。
Medicine (Baltimore). 2024 Mar 1;103(9):e37371. doi: 10.1097/MD.0000000000037371.
7
Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in -Associated Prostate Cancer Resulting From Biallelic Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.双等位基因回复突变导致的前列腺癌对聚（ADP-核糖）聚合酶抑制剂奥拉帕尼获得性耐药恢复了种系和体细胞功能丧失突变。
JCO Precis Oncol. 2018;2. doi: 10.1200/PO.17.00176. Epub 2018 Feb 14.
8
A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with mutation diagnosed by liver biopsy.一例经肝活检诊断为伴有突变的转移性治疗后出现的小细胞/神经内分泌前列腺癌病例。
IJU Case Rep. 2022 Jun 29;5(6):431-435. doi: 10.1002/iju5.12501. eCollection 2022 Nov.
9
Treatment-emergent neuroendocrine prostate cancer with a germline mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance.携带种系突变的治疗相关性神经内分泌前列腺癌：与铂类药物/PARP 抑制剂耐药相关的候选回复突变的鉴定。
Cold Spring Harb Mol Case Stud. 2021 Feb 19;7(1). doi: 10.1101/mcs.a005801. Print 2021 Feb.
10
Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with mutation: a case report.奥拉帕利治疗携带**基因突变**的神经内分泌前列腺癌后消退并发间质性肺炎：一例报告
Int Cancer Conf J. 2023 Jan 3;12(2):131-136. doi: 10.1007/s13691-022-00592-5. eCollection 2023 Apr.

本文引用的文献

1
Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta-analysis.神经内分泌前列腺癌的基因组改变：一项系统综述和荟萃分析。
BJUI Compass. 2023 Jan 2;4(3):256-265. doi: 10.1002/bco2.212. eCollection 2023 May.
2
Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with mutation: a case report.奥拉帕利治疗携带**基因突变**的神经内分泌前列腺癌后消退并发间质性肺炎：一例报告
Int Cancer Conf J. 2023 Jan 3;12(2):131-136. doi: 10.1007/s13691-022-00592-5. eCollection 2023 Apr.
3
Two cases of CRPC with mutation treated by olaparib after favorable response to cisplatin.
两例对顺铂治疗有良好反应后接受奥拉帕利治疗的携带突变的去势抵抗性前列腺癌（CRPC）病例。
IJU Case Rep. 2022 Oct 9;6(1):37-40. doi: 10.1002/iju5.12543. eCollection 2023 Jan.
4
A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with mutation diagnosed by liver biopsy.一例经肝活检诊断为伴有突变的转移性治疗后出现的小细胞/神经内分泌前列腺癌病例。
IJU Case Rep. 2022 Jun 29;5(6):431-435. doi: 10.1002/iju5.12501. eCollection 2022 Nov.
5
Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.神经内分泌癌作为前列腺癌患者的独立预后因素：一项基于人群的研究。
Front Endocrinol (Lausanne). 2021 Dec 8;12:778758. doi: 10.3389/fendo.2021.778758. eCollection 2021.
6
Treatment-emergent neuroendocrine prostate cancer with a germline mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance.携带种系突变的治疗相关性神经内分泌前列腺癌：与铂类药物/PARP 抑制剂耐药相关的候选回复突变的鉴定。
Cold Spring Harb Mol Case Stud. 2021 Feb 19;7(1). doi: 10.1101/mcs.a005801. Print 2021 Feb.
7
Neuroendocrine and Aggressive-Variant Prostate Cancer.神经内分泌和侵袭性变异型前列腺癌
Cancers (Basel). 2020 Dec 16;12(12):3792. doi: 10.3390/cancers12123792.
8
Metastatic Castration-Resistant Prostate Cancer with Neuroendocrine Transformation and BRCA 1 Germ-Line Mutation: A Case Report and Literature Review.伴有神经内分泌转化和BRCA 1种系突变的转移性去势抵抗性前列腺癌：病例报告及文献综述
Onco Targets Ther. 2020 Aug 12;13:8049-8054. doi: 10.2147/OTT.S264347. eCollection 2020.
9
Olaparib for Metastatic Castration-Resistant Prostate Cancer.奥拉帕利治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28.
10
Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer.分子检测确定了一名致命性、治疗中出现的神经内分泌前列腺癌患者的卓越反应决定因素并指导精准治疗。
Cureus. 2019 Jul 22;11(7):e5197. doi: 10.7759/cureus.5197.